Testing TAVNEOS for ear, nose, and throat symptoms in GPA
Treatments studied
Part of Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests a new drug called TAVNEOS (avacopan) for people with Granulomatosis with Polyangiitis (GPA) whose symptoms affect the ears, nose, or throat. The goal is to see if this drug can reduce inflammation and improve these symptoms better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Granulomatosis with Polyangiitis (GPA), a disease that causes inflammation in blood vessels.
- You must have active symptoms in your ears, nose, or throat (like nasal bleeding, voice changes, or hearing loss) in the past month.
- You must be 18 years or older.
- You must not have taken the study drug TAVNEOS in the last 6 months.
- You must not have severe kidney disease (like needing dialysis or a kidney transplant) or active infections like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This study looks at eye problems in people who have a disease called granulomatosis with polyangiitis (GPA), which is a type of blood vessel inflammation that can also affect the eyes. They want to understand what eye issues happen in this disease.
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
This study looks at inflammation in the ear, nose, and throat area in people with different conditions, including nasal polyps, severe asthma, eGPA (a rare blood vessel disease), and GPA (another rare disease). It compares them to healthy volunteers to better understand what causes local inflammation.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
Hear when a new Granulomatosis With Polyangiitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.